Lung cancer trials aim to improve patient outcomes

TROG Cancer Research is at the forefront of efforts to improve the prognosis for people diagnosed with the leading cause of death from cancer – lung cancer.

While lung cancer is the fifth most common cancer in Australia, it is responsible for one in five cancer deaths. For people diagnosed with the disease, the chance of surviving lung cancer for at least five years is just 19 per cent.

Overall, the chance that a man will develop lung cancer in his lifetime is about 1 in 15; for a woman, the risk is about 1 in 17.

Non-small cell is the most common type of lung cancer, accounting for approximately 85 per cent of cases. Radiation therapy can be used to locally treat advanced non-small cell lung cancer.

TROG Cancer Research trials aim to determine more effective radiation therapy treatment regimes that result in better survival rates. Generous financial support and willing trial participants are the key to achieving this goal.

Lung cancer trials, Lung Cancer Radiation Therapy Trials, TROG Cancer Research

Lung cancer trials now recruiting

Our clinical trials typically involve testing new hypothesizes aimed at developing better treatment regimes to help improve survival rates and quality of life for people with lung cancer. View our current trials below to learn more about the lung cancer clinical trials that TROG Cancer Research is currently recruiting participants for.

ALTG 14/002/CT0135/TROG 16.01 – NIVORAD

Randomised phase 2 trial of nivolumab and radiotherapy versus nivolumab alone in advanced non-small cell lung cancer progressing after first line chemotherapy

TROG 03.07 – Non Small Cell Lung Cancer

A Randomised Phase II Study of Two Regimens of Palliative Chemoradiation Therapy in the Management of Locally Advanced Non Small Cell Lung Cancer

TROG 09.02 – CHISEL

A randomised phase III trial of highly conformal hypofractionated image guided (“Stereotactic”) radiotherapy (HypoRT) versus conventionally fractionated radiotherapy (ConRT) for inoperable early stage I non small cell lung cancer.

TROG 11.03 – PLUNG_GP/ALTG

A randomised phase III trial of high dose palliative radiotherapy (HDPRT) versus concurrent chemotherapy and HDPRT (C-HDPRT) in patients with good performance status, locally advanced/small volume metastatic NSCLC not suitable for radical chemo-radiotherapy.

TROG 13.01 – SAFRON II/ALTG 13.001

Stereotactic body radiotherapy in lung metastases from any non haematological primary cancer.

TROG 17.02 – OUTRUN

Randomised phase II trial of Osimertinib with or without stereotactic radiosurgery for EGFR mutated NSCLC with brain metastases

TROG 20.01 – CHEST RT

Chemotherapy Immunotherapy in Extensive Stage Small Cell with Thoracic Radiation therapy

TROG 99.05 – Lung Tumour Volume

Tumour Volume as an Independent Prognosis Factor in Patients with Non-Small Cell Lung Cancer: A Protocol for a Progressive Database
Lung cancer trials, Lung Cancer Radiation Therapy Trials, TROG Cancer Research
Lung Cancer Trials

TROG 09.02 CHISEL

The TROG 09.02 CHISEL study aimed to investigate if Stereotactic Ablative Body Radiotherapy (SABR) was more effective than standard radiotherapy for patients with non-small cell lung cancer (early-stage lung cancer).

This trial found that for patients with early-stage lung cancer, SABR was more effective in controlling cancer growth, resulting in longer life expectancy and was just as safe as traditional radiotherapy. 89% of cancers were controlled two years after SABR treatment and this compared to 65% for conventional radiotherapy, and there was also a clear benefit in overall survival.

As the SABR technique is much more precise, only the cancer was treated and the surrounding healthy tissue was unaffected. TROG Cancer Research has shown for the first time that this treatment was not only more effective but also more convenient with fewer hospital attendances for the patient.

Recent lung cancer trial success

In investigating the complex relationship between lung tumour volume and survival in patients, TROG 99.05 showed that a larger tumour size should not exclude lung cancer patients from curative (chemo) radiation therapy. Over 500 people with pathologically proven stage I-III non-small cell lung cancer participated in the trial. Volumes of the primary tumour (T) and enlarged nodes (N) were measured according to a standardised protocol.

Larger primary tumour volume had been associated with shorter survival. However, after adjusting for the effects of T and N stage, there was no evidence for an association. There was evidence, however, that larger primary tumour volume was associated with an increased risk of dying, independently of T and N stage, in the first 18 months but not beyond.

Donate today to support lung cancer trials – it’s easy!

One in three Australians will be diagnosed with cancer and donations are vital in ensuring TROG Cancer Research continues to produce and support quality clinical cancer research. Our cancer trials save lives and change lives, but we need your help. All donations of $2.00 and over are fully tax-deductible and you will receive a receipt from TROG Cancer Research.